Clinical trials · Ohio
Locally Advanced Solid Tumor clinical trials in Ohio
We’re tracking 110 recruiting locally advanced solid tumor studies with a site in Ohio — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Cleveland, OhioAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Cincinnati, OhioAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Cleveland, OhioAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Canton, OhioAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Cincinnati, OhioAges 18 years+ - NCT06249048RecruitingPhase 1/Phase 2
Study of STX-001 injection for advanced solid tumors
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
Cleveland, OhioAges 18 years+ - NCT06251310RecruitingPhase 1
Testing SW-682 in Advanced Solid Tumors
This trial tests a new drug (SW-682) for people with advanced solid tumors that have stopped responding to standard treatments. It focuses on cancers with specific gene changes (NF2 or Hippo pathway) and aims to see if the drug can shrink tumors or slow their growth.
Cleveland, OhioAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06425926RecruitingPhase 1/Phase 2
Study of GIM-531 in advanced solid tumors
This study tests a new oral drug, GIM-531, alone and in combination with an anti-PD-1 therapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Cincinnati, OhioAges 18 years+ - NCT06521554RecruitingPhase 1
Study of NVL-330 for HER2-altered advanced lung cancer
This trial tests a new oral drug called NVL-330 for people with advanced NSCLC whose tumors have a specific change in the HER2 gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Columbus, OhioAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Columbus, OhioAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Cleveland, OhioAges 12 years+ - NCT06669117RecruitingPhase 1/Phase 2
VERT-002 for solid tumors with MET changes
This trial tests a new drug, VERT-002, for people with advanced solid tumors, including non-small cell lung cancer (NSCLC), that have specific changes in the MET gene. It aims to see if the drug can shrink tumors or stop them from growing when other treatments haven't worked or aren't available.
Canton, OhioAges 18 years+ - NCT06760819RecruitingPhase 2
Sevacertinib for solid tumors with HER2 mutations
This study tests an oral tablet called sevacertinib in people with solid tumors (not lung cancer) that have a HER2 mutation. It aims to see how well the drug works and how safe it is for people who have tried other treatments or have no good options left.
Cleveland, OhioAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Cleveland, OhioAges 18 years+ - NCT06973564RecruitingPhase 1/Phase 2
JAB-23E73 for Advanced Solid Tumors with KRAS Changes
This trial tests a new drug called JAB-23E73 for people with advanced solid tumors that have a specific change in the KRAS gene. It may be an option if previous treatments have stopped working or are not suitable.
Cleveland, OhioAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Cleveland, OhioAges 18 years+ - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Maumee, OhioAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Columbus, OhioAges 18 years+ - NCT07094204RecruitingPhase 1
A study of ASP5834 for adults with solid tumors and KRAS mutations
This trial is testing a new drug called ASP5834 for people with advanced solid tumors that have a specific change in the KRAS gene. The study will find the best dose and see if it helps shrink tumors.
Cleveland, OhioAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Cleveland, OhioAges 18 years+ - NCT03093116RecruitingPhase 1/Phase 2
Repotrectinib for ALK, ROS1, or NTRK tumor gene changes
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Cleveland, OhioAges 12 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Cleveland, OhioAges 18 years+
Locally Advanced Solid Tumor trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting locally advanced solid tumor studies listed above.
- Cleveland Clinic · 7 studies
- University Hospitals Cleveland Medical Center · 5 studies
- The Ohio State University Wexner Medical Center · 4 studies
- Gabrail Cancer Center · 2 studies
- Research Site · 2 studies
- University of Cincinnati Cancer Center-UC Medical Center · 2 studies
- Clinical Study Site
- Exelixis Clinical Site
What taking part in a locally advanced solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Locally Advanced Solid Tumor trials in other states
Common questions
- Are there locally advanced solid tumor clinical trials in Ohio?
- Yes. We're currently tracking 110 recruiting locally advanced solid tumor studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced solid tumor study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced solid tumor studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.